AstraZeneca Plc delivered a third consecutive year of revenue growth in 2023 as medicines across three of its therapy areas delivered a double-digit increase and the company launched new products. Speaking to journalists on 8 February, Pascal Soriot, the chief executive, predicted more growth in 2014 and at least 15 new product launches by 2030. “We are seeing growth across all geographies,” he said, adding that this is being driven by new technologies.
